Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab in Chronic Rhinosinusitis with Nasal Polyps
CTR20221191Phase 3Completed
- Sponsor
- GSK
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of depemokimab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by GSK. Started May 2022; status: completed.
02
Drugs
depemokimab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on CTR20221191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221191.